Asarfi Hospital

  • Market Cap: Micro Cap
  • Industry: Hospital
  • ISIN: INE0DN001027
  • NSEID:
  • BSEID: 543943
INR
207.35
-7.55 (-3.51%)
BSENSE

Sep 01, 03:30 PM

BSE+NSE Vol: 50000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

50.0 k (39.66%) Volume

Shareholding (Jun 2026)

FII

0.00%

Held by 0 FIIs

DII

2.97%

Held by 0 DIIs

Promoter

61.17%

Why is Asarfi Hospital Ltd falling/rising?

01-Sep-2026

As of 31-Aug, Asarfi Hospital Ltd's stock price is currently at 214.90, reflecting a 1.22% increase and indicating a potential recovery in investor sentiment after recent declines. The stock has significantly outperformed the Sensex over various periods, despite a recent decline in investor participation.

As of 31-Aug, Asarfi Hospital Ltd's stock price is rising, currently at 214.90, with a change of 2.6 (1.22%) upward. The stock has shown a positive performance today, outperforming its sector by 1.35%. Additionally, this rise follows a trend reversal after two consecutive days of decline, indicating a potential recovery in investor sentiment.<BR><BR>Over the past week, the stock has increased by 1.37%, while the benchmark Sensex has decreased by 0.53%. In the last month, Asarfi Hospital Ltd has gained 3.87%, contrasting with a 1.46% drop in the Sensex. Year-to-date, the stock has risen by 14.25%, significantly outperforming the Sensex, which has fallen by 9.70%. Over the past year, the stock has surged by 77.75%, while the Sensex has declined by 3.57%. This strong performance over various periods suggests robust investor confidence in the company.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume on 28 August falling by 21.05% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, indicating that it can still attract investors. The current price is above the 200-day moving average but below the shorter-term moving averages, which may suggest mixed signals regarding the stock's momentum.<BR><BR>Overall, the combination of recent gains, strong historical performance, and sector outperformance contributes to the rising stock price of Asarfi Hospital Ltd.

View full answer

Who are in the management team of Asarfi Hospital?

01-Sep-2026

The management team of Asarfi Hospital includes Udai Pratap Singh (Managing Director), Madhuri Singh (Executive Director), Sukanti Kumar Das (Director), Amit Kumar Barnwal (Independent Director), Rajkumari Sharma (Independent Director), and Seepika Gupta (Company Secretary & Compliance Officer).

The management team of Asarfi Hospital includes the following individuals:<BR><BR>1. Udai Pratap Singh - Managing Director<BR>2. Madhuri Singh - Executive Director<BR>3. Sukanti Kumar Das - Director<BR>4. Amit Kumar Barnwal - Independent Director<BR>5. Rajkumari Sharma - Independent Director<BR>6. Seepika Gupta - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about Asarfi Hospital or its operations, feel free to ask!

View full answer

What does Asarfi Hospital do?

01-Sep-2026

Asarfi Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2005 and converted to a public limited company in 2012. As of June 2026, it reported net sales of 48 Cr and a net profit of 4 Cr, with a market cap of INR 418 Cr.

Overview: <BR>Asarfi Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Asarfi Hospital Limited was originally incorporated as a Private Limited Company on October 4, 2005, under the name "Asarfi Hospital Private Limited." The company later converted its status to Public Limited and changed its name to "Asarfi Hospital Limited" on February 08, 2012. The most recent quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 48 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 4 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 418 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.46 <BR>Return on Equity: 17.48% <BR>Price-to-Book: 4.13 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

View full answer

Who are the peers of the Asarfi Hospital?

01-Sep-2026

Asarfi Hospital's peers include Shalby, GPT Healthcare, Lotus Eye Hospital, Aashka Hospitals, Chandan Healthcare, Unihealth Hospital, Aprameya Engineering, and Vaidya Sane. Asarfi Hospital has a good management risk rating and the highest 1-year return at 77.75%, outperforming its peers.

Peers: The peers of Asarfi Hospital are Shalby, GPT Healthcare, Lotus Eye Hospit, Aashka Hospitals, Chandan Healthca, Unihealth Hosp, Aprameya Enginee, and Vaidya Sane.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare and Aprameya Enginee, while Good management risk is found at Asarfi Hospital, Chandan Healthca, and Unihealth Hosp. Average management risk is noted at Shalby, while Below Average management risk is present at Lotus Eye Hospit, Aashka Hospitals, and Vaidya Sane, and the rest. Growth is Excellent at Chandan Healthca and Unihealth Hosp, Good at Asarfi Hospital, while Below Average growth is seen at Shalby, GPT Healthcare, Lotus Eye Hospit, Aashka Hospitals, and the rest. Capital Structure is Excellent at GPT Healthcare and Unihealth Hosp, Good at Asarfi Hospital, Shalby, and Aprameya Enginee, while Average capital structure is noted at Aashka Hospitals and Below Average at Lotus Eye Hospit and Vaidya Sane.<BR><BR>Return Snapshot: Asarfi Hospital has the highest 1-year return at 77.75%, while Lotus Eye Hospit has the lowest at -6.51%. Compared to its peers, Asarfi Hospital's return significantly outperforms the others. Additionally, Chandan Healthca, Unihealth Hosp, Aprameya Enginee, and Vaidya Sane all reported a six-month return of 0.00%.

View full answer

How big is Asarfi Hospital?

01-Sep-2026

As of 31st August, Asarfi Hospital Ltd has a market capitalization of 418.00 Cr, with recent Net Sales of 183.76 Cr and a Net Profit of 17.81 Cr. The latest balance sheet shows Shareholder's Funds of 80.98 Cr and Total Assets of 163.89 Cr.

As of 31st August, Asarfi Hospital Ltd has a market capitalization of 418.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Asarfi Hospital reported Net Sales of 183.76 Cr and a Net Profit of 17.81 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 80.98 Cr and Total Assets of 163.89 Cr.

View full answer

Which are the latest news on Asarfi Hospital?

01-Sep-2026

Should I buy, sell or hold Asarfi Hospital Ltd?

08-Aug-2026

Are Asarfi Hospital Ltd latest results good or bad?

07-Aug-2026

Asarfi Hospital Ltd's latest results show mixed performance: while net profit increased 9.19% year-on-year, it fell 27.68% quarter-on-quarter, and revenue grew 28.89% year-on-year but slightly declined 1.87% from the previous quarter. The drop in profitability margins has raised concerns, leading to a negative market reaction.

Asarfi Hospital Ltd's latest results present a mixed picture. In the fourth quarter of FY26, the company reported a net profit of ₹3.92 crore, which is a significant decline of 27.68% compared to the previous quarter. However, on a year-on-year basis, net profit increased by 9.19%. <BR><BR>Revenue for the same quarter was ₹45.24 crore, reflecting a slight decrease of 1.87% from the previous quarter but a robust increase of 28.89% year-on-year. While the top-line growth is encouraging, the decline in profitability metrics raises concerns. The operating margin fell sharply to 17.06%, down from 21.93% in the previous quarter, and the PAT margin also decreased to 8.66%, down from 11.76%. <BR><BR>Overall, while the revenue growth year-on-year is positive, the sequential decline in both net profit and operating margins indicates operational challenges that the company needs to address. This has led to a negative market reaction, with the stock experiencing a significant drop in value following the results. Investors may want to consider these factors carefully when evaluating the company's performance.

View full answer

When is the next results date for Asarfi Hospital Ltd?

05-Aug-2026

The next results date for Asarfi Hospital Ltd is 07 August 2026.

The next results date for Asarfi Hospital Ltd is scheduled for 07 August 2026.

View full answer

Is Asarfi Hospital overvalued or undervalued?

17-Nov-2025

As of November 14, 2025, Asarfi Hospital is considered overvalued with a PE ratio of 31.38 and an EV to EBITDA of 16.34, despite strong stock performance, indicating it may not be an attractive investment compared to peers like Apollo Hospitals and Max Healthcare.

As of 14 November 2025, Asarfi Hospital's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently assessed as overvalued. Key ratios include a PE ratio of 31.38, an EV to EBITDA of 16.34, and a PEG ratio of 0.20, which suggests growth potential relative to its valuation. <BR><BR>In comparison to peers, Apollo Hospitals has a significantly higher PE ratio of 63.77 and an EV to EBITDA of 33.53, while Max Healthcare is marked as very expensive with a PE of 89.07. Despite the recent strong stock performance, with a year-to-date return of 75.1% compared to the Sensex's 8.22%, the elevated valuation metrics indicate that Asarfi Hospital may not present an attractive investment opportunity at current levels.

View full answer

How has been the historical performance of Asarfi Hospital?

15-Nov-2025

Asarfi Hospital experienced significant growth in net sales and profits from Mar'24 to Mar'25, with net sales rising to 120.57 Cr and profit after tax increasing to 10.58 Cr. However, cash flow from operating activities turned negative, indicating challenges in cash management despite strong revenue performance.

Answer:<BR>The historical performance of Asarfi Hospital shows significant growth from the previous year, with net sales increasing from 84.40 Cr in Mar'24 to 120.57 Cr in Mar'25. Total operating income mirrored this growth, rising to 120.57 Cr from 84.40 Cr. The total expenditure also increased, from 68.35 Cr to 97.01 Cr, primarily driven by higher raw material costs and other expenses. Operating profit (PBDIT) rose to 31.08 Cr from 17.72 Cr, while profit before tax improved from 6.24 Cr to 14.31 Cr. Consequently, profit after tax saw a substantial increase from 4.16 Cr to 10.58 Cr, resulting in an earnings per share (EPS) growth from 2.11 to 5.38. <BR><BR>In terms of balance sheet performance, shareholder's funds increased to 80.98 Cr from 70.41 Cr, and total liabilities rose to 163.89 Cr from 154.09 Cr. Long-term borrowings also increased significantly from 17.45 Cr to 33.83 Cr. Current assets improved to 58.48 Cr from 45.60 Cr, with notable increases in sundry debtors and inventories. However, cash flow from operating activities turned negative, dropping from 26.00 Cr to -4.00 Cr, while cash flow from financing activities decreased from 36.00 Cr to 12.00 Cr. Overall, Asarfi Hospital demonstrated strong revenue and profit growth, despite challenges in cash flow management.

View full answer

Who are the top shareholders of the Asarfi Hospital?

17-Jul-2025

The top shareholders of Asarfi Hospital include Harendra Singh with 18.78%, followed by public shareholder Gopal Singh at 2.4%. Individual investors collectively own 30.86% of the shares, with no pledged promoter holdings or involvement from mutual funds or foreign institutional investors.

The top shareholders of Asarfi Hospital primarily consist of the promoters, with Harendra Singh holding the largest stake at 18.78%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors involved. The highest public shareholder is Gopal Singh, who holds 2.4%. Additionally, individual investors collectively own 30.86% of the shares.

View full answer

What is the technical trend for Asarfi Hospital?

09-Jun-2025

As of May 19, 2025, Asarfi Hospital's technical trend is bullish, supported by a positive MACD and moving averages, although the weekly RSI indicates some potential weakness in momentum.

As of 19 May 2025, the technical trend for Asarfi Hospital has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the daily moving averages also indicate bullish momentum. The Bollinger Bands are bullish on both weekly and monthly time frames, reinforcing the strength of the current trend. However, the weekly RSI is bearish, suggesting some potential weakness in momentum. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and moving averages.

View full answer

Has Asarfi Hospital declared dividend?

06-Jun-2025

No Dividend History Available

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.96 times

 
2

Healthy long term growth as Net Sales has grown by an annual rate of 27.70% and Operating profit at 34.16%

 
3

The company has declared Positive results for the last 5 consecutive quarters

4

With ROCE of 16.5, it has a Very Attractive valuation with a 3 Enterprise value to Capital Employed

5

Increasing Participation by Institutional Investors

6

Market Beating Performance

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 423 Cr (Micro Cap)

stock-summary
P/E

23.00

stock-summary
Industry P/E

67

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.46

stock-summary
Return on Equity

17.48%

stock-summary
Price to Book

4.15

Revenue and Profits:
Net Sales:
48 Cr
(Quarterly Results - Jun 2026)
Net Profit:
4 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.7%
0%
2.7%
6 Months
31.4%
0%
31.4%
1 Year
65.28%
0%
65.28%
2 Years
220.48%
0%
220.48%
3 Years
68.99%
0%
68.99%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Asarfi Hospital for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) 2015.

25-Aug-2026 | Source : BSE

We hereby inform you that the meeting of the Board of Directors of Asarfi Hospital Limited was held on Tuesday August 25 2026 at 11:00 A.M. at the registered office of the Company at 4th Floor Asarfi Hospital Baramuri B. Polytechnic Dhanbad - 828130

Board Meeting Intimation for Notice Of 21St Annual General Meeting Of Asarfi Hospital Limited.

18-Aug-2026 | Source : BSE

Asarfi Hospital Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 inter alia to consider and approve Notice is hereby given that the 4th Meeting of the Board of Directors of Asarfi Hospital Limited for FY 2026-27 will be held on Tuesday 25 August 2026 at 11:00 A.M. at the Registered Office of the Company at Baramuri Bishunpur Polytechnic Dhanbad Jharkhand- 828130.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

08-Aug-2026 | Source : BSE

Submission of Newspaper Advertisement of unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30 2026.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
27.70%
EBIT Growth (5y)
34.16%
EBIT to Interest (avg)
4.52
Debt to EBITDA (avg)
2.00
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.92
Tax Ratio
24.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.97%
ROCE (avg)
8.69%
ROE (avg)
16.01%

Valuation key factors

Factor
Value
P/E Ratio
23
Industry P/E
67
Price to Book Value
3.98
EV to EBIT
18.49
EV to EBITDA
12.51
EV to Capital Employed
3.05
EV to Sales
2.46
PEG Ratio
0.41
Dividend Yield
NA
ROCE (Latest)
16.47%
ROE (Latest)
17.48%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Harendra Singh (18.78%)

Highest Public shareholder

Gopal Singh (2.4%)

Individual Investors Holdings

30.1%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 5.06% vs -1.87% in Mar 2026",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 8.93% vs -27.68% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.53",
          "val2": "45.24",
          "chgp": "5.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.46",
          "val2": "7.72",
          "chgp": "22.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.17",
          "val2": "0.71",
          "chgp": "64.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4.27",
          "val2": "3.92",
          "chgp": "8.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "19.90%",
          "val2": "17.06%",
          "chgp": "2.84%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2026 is 36.38% vs 25.62% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Mar 2026 is 48.96% vs 45.81% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "92.14",
          "val2": "67.56",
          "chgp": "36.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.63",
          "val2": "12.81",
          "chgp": "45.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.96",
          "val2": "2.52",
          "chgp": "-22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "9.34",
          "val2": "6.27",
          "chgp": "48.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.22%",
          "val2": "18.96%",
          "chgp": "1.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -1.13% vs 5.82% in Jun 2026",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 12.78% vs -33.68% in Jun 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Jun'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "86.67",
          "val2": "87.66",
          "chgp": "-1.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "18.60",
          "val2": "17.51",
          "chgp": "6.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.74",
          "val2": "2.50",
          "chgp": "9.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.15",
          "val2": "6.34",
          "chgp": "12.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.46%",
          "val2": "19.97%",
          "chgp": "1.49%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 42.47% vs 44.29% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 57.47% vs 154.33% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "173.50",
          "val2": "121.78",
          "chgp": "42.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "35.27",
          "val2": "24.77",
          "chgp": "42.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.24",
          "val2": "4.08",
          "chgp": "3.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.66",
          "val2": "10.58",
          "chgp": "57.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.33%",
          "val2": "20.34%",
          "chgp": "-0.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQstock-summary

Jun'26
Mar'26
Change(%)
Net Sales
47.53
45.24
5.06%
Operating Profit (PBDIT) excl Other Income
9.46
7.72
22.54%
Interest
1.17
0.71
64.79%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4.27
3.92
8.93%
Operating Profit Margin (Excl OI)
19.90%
17.06%
2.84%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2026 is 5.06% vs -1.87% in Mar 2026

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 8.93% vs -27.68% in Mar 2026

Half Yearly Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
92.14
67.56
36.38%
Operating Profit (PBDIT) excl Other Income
18.63
12.81
45.43%
Interest
1.96
2.52
-22.22%
Exceptional Items
0.00
0.00
Consolidate Net Profit
9.34
6.27
48.96%
Operating Profit Margin (Excl OI)
20.22%
18.96%
1.26%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2026 is 36.38% vs 25.62% in Mar 2025

Direction Arrows
Consolidated Net Profit

Growth in half year ended Mar 2026 is 48.96% vs 45.81% in Mar 2025

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary

Dec'24
Jun'26
Change(%)
Net Sales
86.67
87.66
-1.13%
Operating Profit (PBDIT) excl Other Income
18.60
17.51
6.23%
Interest
2.74
2.50
9.60%
Exceptional Items
0.00
0.00
Standalone Net Profit
7.15
6.34
12.78%
Operating Profit Margin (Excl OI)
21.46%
19.97%
1.49%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is -1.13% vs 5.82% in Jun 2026

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is 12.78% vs -33.68% in Jun 2026

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
173.50
121.78
42.47%
Operating Profit (PBDIT) excl Other Income
35.27
24.77
42.39%
Interest
4.24
4.08
3.92%
Exceptional Items
0.00
0.00
Consolidate Net Profit
16.66
10.58
57.47%
Operating Profit Margin (Excl OI)
20.33%
20.34%
-0.01%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 42.47% vs 44.29% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 57.47% vs 154.33% in Mar 2025

stock-summaryCompany CV
About Asarfi Hospital Ltd stock-summary
stock-summary
Asarfi Hospital Ltd
Micro Cap
Hospital
Asarfi Hospital Limited was originally incorporated as Private Limited Company in the name of "Asarfi Hospital Private Limited" on October 4, 2005 issued by Registrar of Companies, Bihar & Jharkhand. Subsequently, status of the Company was converted into Public Limited and name of the Company was changed to "Asarfi Hospital Limited" vide a fresh Certificate of Incorporation dated February 08, 2012 issued by Registrar of Companies, Jharkhand.
Company Coordinates stock-summary
Icon
No Company Details Available